Equillium (EQ) Projected to Post Earnings on Monday

Equillium (NASDAQ:EQGet Free Report) is projected to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Equillium to post earnings of ($0.22) per share for the quarter.

Equillium Stock Performance

NASDAQ EQ opened at $0.77 on Friday. The stock’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.80. The firm has a market capitalization of $27.39 million, a P/E ratio of -5.52 and a beta of 1.87. Equillium has a fifty-two week low of $0.49 and a fifty-two week high of $2.90.

About Equillium

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

See Also

Earnings History for Equillium (NASDAQ:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.